Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 755Carcinoma, Renal Cell 241Urinary Bladder Neoplasms 213Carcinoma, Transitional Cell 117Breast Neoplasms 102Kidney Neoplasms 100Neoplasms 91Carcinoma, Non-Small-Cell Lung 86Melanoma 83Ovarian Neoplasms 82Colorectal Neoplasms 76Neoplasm Metastasis 71Non-Muscle Invasive Bladder Neoplasms 58Lung Neoplasms 58Pancreatic Neoplasms 49Endometrial Neoplasms 46Sarcoma 45Stomach Neoplasms 42Uterine Cervical Neoplasms 41Carcinoma, Hepatocellular 36Adenocarcinoma 36Wilms Tumor 34Esophageal Neoplasms 33Triple Negative Breast Neoplasms 31Squamous Cell Carcinoma of Head and Neck 31Head and Neck Neoplasms 29Testicular Neoplasms 26Metastatic Castration-resistant Prostate Cancer 25Disease 24Colonic Neoplasms 24

Interventions

zimberelimab 1sacituzumab govitecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urothelial Bladder Carcinoma × Genitourinary × 90 days × Clear all
NCT06133517 2026-03-16

PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer

Fundación para el Progreso de la Oncología en Cantabria

Phase 2 Active not recruiting
70 enrolled
Genitourinary

Urothelial Bladder Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡